Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

December 8, 2025

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2025 Dec 8;67(1743):e201-4 doi:10.58347/tml.2025.1743d

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.

Additional Contributor(s)

Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Discuss the approach to the use of insulin for glycemic control in patients with type 2 diabetes.
Review the insulins available for use in patients with type 2 diabetes.

Select a term to see related articles Admelog Afrezza Apidra Basaglar degludec Fiasp Humalog Humulin insulin Kirsty Lantus Lyumjev Merilog Novolin Novolog ReliOn Rezvaglar Semglee Toujeo type 2 diabetes

View the Comparison Chart: Some Available Insulins for Type 2 Diabetes

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.